Similar investigations have also revealed that EIF3M exhibits overexpression in prostate cancer and triple-negative breast cancer, with cellular experiments confirming significant growth inhibition in tumor cells following EIF3M knockdown (Guo et al., 2024; Han et al., 2020). The gene discussed is EIF3M; the disease is triple-negative breast carcinoma.